Hims vs Oak Longevity: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
Hims beats Oak Longevity overall, scoring 7.9/10 vs 7.5/10. Oak Longevity is more affordable at $130/mo vs $199/mo. Choose Hims for men who want glp-1 access from a well-known, publicly traded. Choose Oak Longevity for budget-conscious users who want one of the cheapest compound.
A side-by-side comparison of Hims and Oak Longevity covering pricing, scores, medication types, insurance, and more to help you decide.
Hims
#12 of 42One of the largest and most recognized men's telehealth platforms in the US. In 2026 Hims signed a direct partnership with Novo Nordisk adding FDA-approved brand Wegovy (injection and pill) and Ozempic alongside their existing compounded semaglutide program.
Visit HimsOak Longevity
#23 of 42Telehealth platform offering compounded semaglutide and tirzepatide at the lower end of market pricing, alongside an oral Wegovy option, brand-name FDA-approved GLP-1s, and a longevity stack (NAD+, Glutathione, Sermorelin, Tesamorelin). Distinctive non-subscription billing — patients pay each month manually rather than auto-renew.
Visit Oak Longevity| Feature | Hims | Oak Longevity |
|---|---|---|
| Our Score | 7.9/10 | 7.5/10 |
| Starting Price | $199/mo | $130/mo |
| Medication Type | Both | Both |
| Insurance Accepted | No | No |
| Best For | Men who want GLP-1 access from a well-known, publicly traded telehealth brand — now with FDA-approved brand access via the 2026 Novo Nordisk partnership | Budget-conscious users who want one of the cheapest compounded GLP-1 entries plus a no-subscription billing model and a longevity-stack add-on (NAD+, Sermorelin) |
| Ranking | #12 | #23 |
Pros & Cons Compared
Hims
Pros
- +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
- +2026 Novo Nordisk partnership — FDA-approved Wegovy injection, Wegovy pill, and Ozempic now available directly through Hims
- +$199/mo all-inclusive for compounded semaglutide with consultations and free shipping
- +Polished app and web experience — one of the best user interfaces in men's telehealth
Cons
- −Brand-name pricing jumps to $599/mo for Wegovy injection — not competitive with LillyDirect/NovoCare cash prices
- −Generic support experience — large patient volume means less personalized attention
- −'Hims Oral Kit' is NOT a GLP-1 (it's a non-GLP-1 combo: metformin + bupropion + topiramate + B12 + naltrexone) — easy to confuse with their compounded semaglutide program
- −Higher price than compounded-only competitors like TrimRx or Enhance MD for the same compounded product
Oak Longevity
Pros
- +$130/mo for compounded semaglutide is among the cheapest entries on the market — Sprout Health ($99) and Sesame Care ($99) are lower, but Oak undercuts most mid-tier platforms
- +Compounded tirzepatide at $199/mo is competitively priced for a GLP-1+GIP dual agonist
- +No-subscription model — patients are not auto-charged each month, choose to renew manually. Reduces unwanted recurring charges
- +Broadest medication mix on the platform: compounded sema + tirz, oral Wegovy, brand Wegovy/Ozempic/Zepbound/Mounjaro, plus longevity peptides (NAD+, Glutathione, Sermorelin, Tesamorelin)
- +Money-back guarantee if not approved by physician — useful safety net for borderline-eligibility patients
- +Free shipping and free health coaching included in every program
Cons
- −Brand-name pricing ($1,200-$1,500/mo) is significantly above market — NovoCare direct pricing for Wegovy is $349/mo, LillyDirect Zepbound $299/mo. Never buy brand-name through Oak
- −No published lab panels, no specialty (obesity medicine) physicians disclosed — clinical depth is shallow
- −'Up to 50% cheaper than competitors' marketing claim is unverified and inconsistent — depends on which competitor and which medication tier
- −'Longevity' framing pushes users toward add-on products (NAD+, Sermorelin, Tesamorelin) that have limited clinical evidence for weight loss specifically
- −Newer brand without disclosed company history, founding date, or executive team on landing pages
- −Three-month plans are billed upfront — pricing transparency is good, but commit-up-front is a friction point for users testing the platform
Our Verdict
Hims edges out Oak Longevity with a score of 7.9/10 vs 7.5/10. If budget is your priority, Oak Longevity starts at $130/mo compared to Hims's $199/mo. Choose Hims if you want: men who want glp-1 access from a well-known, publicly traded telehealth brand — now with fda-approved brand access via the 2026 novo nordisk partnership. Choose Oak Longevity if you want: budget-conscious users who want one of the cheapest compounded glp-1 entries plus a no-subscription billing model and a longevity-stack add-on (nad+, sermorelin).